Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Sedana Medical Q3 - Risk for slower sales ramp-up in coming quarters

Sedana Medical

Redeye lowers its sales estimates for 2022e by 20% from SEK149m to SEK119m. While we see the market for mechanically ventilated patients opting for normalization in 2023, we highlight that UK approval is still not in place, and staffing shortages could linger, negatively affecting Sedana Medical’s sales and training activities as we move into the next year. We lower our fair value range somewhat following the report.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments


Sedana Medical Q3 - Risk for slower sales ramp-up in coming quarters

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.